Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: The Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT)

Canadian Journal of Cardiology

Volumn 19, Issue 5, 2003, Pages 487-491

  Burton, Jeffrey R ^a,d   Teo, Koon K ^a,d,e   Buller, Christopher E ^b   Plante, Sylvain ^c   Catellier, Diane ^d,f   Tymchak, Wayne ^a   Taylor, Dylan ^a   Dzavik, Vladimir ^a,g   Montague, Terrence J ^a,d,h  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f University of North Carolina at Chapel Hill   (United States)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Atherosclerosis; Cholesterol; Simvastatin

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ENALAPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGE; AGED; ANAMNESIS; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; FACTORIAL ANALYSIS; FEMALE; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK FACTOR; SEX; SMOKING HABIT; BLOOD; CANADA; CORONARY ARTERY ATHEROSCLEROSIS; HOSPITALIZATION; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; TREATMENT OUTCOME;

AGED; ALBERTA; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; HUMANS; MALE; MIDDLE AGED; QUEBEC; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0038689511     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
3. Shepherd J, Cobbe SM, Ford I, et al, for the West Of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
4. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
5. Downs JR, Clearfield M, Weis S, et al, for the AFCAPS/TexCAPS research group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
6. Miettinen TA, Pyorala K, Olsson AG, et al, for the Scandinavian Simvastatin Study Group. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211-8.
7. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345:1274-5.
8. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetic Care 1997;20:614-20.
9. Pederson TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998;81:333-5.
10. West of Scotland Coronary Prevention Group. West of Scotland coronary prevention study: Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996;348:1339-42.
11. Sacks FM, Tonkin AM, Shepherd J, et al, for the Prospective Pravastatin Pooling Project Investigators Group. Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project Circulation 000;102:1893-900.
12. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-12.
13. Brown BG, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
14. Waters D, Higginson L, Gladstone P, et al, the CCAIT Study Group. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis intervention Trial. Circulation 1994;89:959-68.
15. MAAS Investigators. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8.
16. Herd JA, Ballantyne CM, Farmer JA, et al, for the LCAS Investigators. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997;80:278-86.
17. Teo KK, Burton JR, Buller CE, et al, for the SCAT Investigators. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The Simvastatin/enalapril Coronary Atherosclerosis Trials (SCAT). Circulation 2000;102:1748-54.
18. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Sone PH, for the Harvard Atherosclerosis Reversibility Project (HARP) Effect of coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. Lancet 1994;344:1182-6.